Adaptive
Seattle, United States · 50 employees
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from ful
Funding history
- Corporate Round — Undisclosed — Mar 2026
- Seed — $7.0M — Apr 2025
- Series A — $19.0M — Jul 2024
- Grant — Undisclosed — Sep 2022
Recent signals
- Mar 05, 2026: Raised funding in Corporate Round
- Apr 22, 2025: Raised $7.0M in Seed
- Feb 04, 2025: Adaptive and Rapid Addition Announce Partnership for Best-in-class FIX Capabilities
- Jul 15, 2024: Raised $19.0M in Series A
- Sep 12, 2022: Raised funding in Grant
See plans & pricing → Track Adaptive’s funding, hiring, and signals — with verified contacts — on Fundz.